Table 1

Clinical and molecular data of the patients.
Case
 Sex
 Age
 Site
 OS
 Status
 7p EGFR
 1q
 4p/4q
 7q
 12q CDK4
 12q MDM2
 13q
 -10q
C29
 M
 39
 T
 46
 A
 A






C34
 F
 81
 P-O
 4
 A
 A





L
C35
 M
 51
 T
 3
 D
 A





L
C35b
 F
 66
 P
 1
 A
 A
 A




L
C36
 F
 55
 T-P
 18
 A
 A





L
C38b
 F
 45
 T-P
 2
 A
 A





L
C42
 M
 70
 T-P-TA
 2
 D
 A






C47
 M
 60
 T
 10
 A
 A






C33
 F
 61
 T
 16
 D
 A

A
A
L
C26
 M
 52
 F-T-P
 3
 D
 A


A

L
C36b
 M
 41
 T
 10
 A



A
 A
L
C48
 M
 74
 T
 7
 D



A
A
C28
 F
 77
 T
 4
 D





A
C39b
 M
 53
 F
 0
 D

A


A
 L
C32
 M
 60
 T-P
 8
 D




A

C30
 M
 79
 T-P
 1
 D







C31
 M
 79
 O
 6
 D







C37b
 M
 75
 T
 0
 D






L
C43
 F
 53
 P-O
 3
 A







C46
 M
 59
 T
 9
 D







Clinical data: sex (M male, F female), tumor site (T temporal, P parietal, O occipital, F frontal and T thalamus), overall survival (OS) in months, and status (D death, A Alive).

Molecular data: (A) amplification, (L) loss.

Ruano et al. Molecular Cancer 2006 5:39   doi:10.1186/1476-4598-5-39